Anne G. Loft

Palle Juul Jensens Boulevard 99
Arhus, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

Journal: EULAR rheumatology open
Published: June 29, 2026

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial.

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial.

Journal: EULAR rheumatology open
Published: June 29, 2026

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Journal: EULAR rheumatology open
Published: June 29, 2026

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Journal: The Journal of rheumatology
Published: June 15, 2026

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Journal: The Journal of rheumatology
Published: June 15, 2026

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study.

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: a European cohort study.

Journal: Joint bone spine
Published: May 13, 2026

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study.

Site-specific articular response to TNF inhibitor in axial spondyloarthritis: A European cohort study.

Journal: Joint bone spine
Published: May 13, 2026

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.

Journal: Annals of the rheumatic diseases
Published: February 11, 2026

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Journal: RMD open
Published: October 28, 2025

Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing.

Assessing internal construct validity of DAPSA and DAPSA28 in psoriatic arthritis: a European observational study using confirmatory factor analysis and additional psychometric testing.

Journal: RMD open
Published: July 07, 2025

Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT.

Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT.

Journal: RMD open
Published: July 02, 2025

Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care.

Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care.

Journal: Therapeutic advances in musculoskeletal disease
Published: June 16, 2025
Showing 1-12 of 88

Last Updated: 09/26/2026